spacer
home > ict > winter 2021 > digitalisation of clinical trials
PUBLICATIONS
International Clinical Trials

Digitalisation of Clinical Trials


As the pharmaceutical industry evolves, there is no denying that it is hungry for new efficiencies in drug development. The globalisation of clinical trials, growth in biologics and personalised medicines, and increased competition have all fundamentally changed the clinical trials landscape and driven a desire for further improved methods and technologies that will streamline processes, fast-track drug approval and commercialisation, and deliver a return on R&D investment.

Given the challenging clinical trials landscape, it is not surprising to learn that return on pharma R&D investment is on a downward trajectory – with data demonstrating a sustained decline from 10.1% in 2010 to 3.2% in 2017 (1). Eliminating increased costs and risks have prompted many big pharma companies to “count on the adoption of digitalisation to increase the efficiency of clinical trials”, according to Deloitte (2). Combine that with consequences of the COVID-19 pandemic and the need for a reduction in physical touchpoints and face-to-face interactions, it is evident that digital technologies are starting to “reshape each step in the clinical trial process – from study design to close out”.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nathan Kohner has been with Almac since 2005, and has over 15 years’ experience in clinical trial supply chain operations including cold chain distribution and project management and supply chain management. This wealth of experience has given him a passion in delivering excellence in customer service to help reduce timelines and clinical trial complexity for sponsors. In his current position as Label Solutions Manager, he is responsible for providing innovative solutions to product labelling needs for sponsors. Nathan graduated with a degree in Mathematics from Edinburgh University, Scotland, and has a diploma in Management and Leadership.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIST Softgels

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement